Nomura Holdings’s Supernus Pharmaceuticals SUPN Stock Holding History

Nomura Holdings’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24,869	Closed	-$1.19M	–	2153
2025 Q3	$1.19M	Buy	+24,869	New	+$1M	﹤0.01%	1343
2023 Q2	–	Sell	-6,000	Closed	-$217K	–	1624
2023 Q1	$217K	Buy	+6,000	New	+$231K	﹤0.01%	1222
2019 Q4	–	Sell	-10,481	Closed	-$280K	–	1328
2019 Q3	$280K	Sell	10,481 -12,353	-54%	-$366K	﹤0.01%	1040
2019 Q2	$755K	Sell	22,834 -21,540	-49%	-$738K	﹤0.01%	887
2019 Q1	$1.58M	Buy	44,374 +17,097	+63%	+$636K	0.01%	714
2018 Q4	$904K	Sell	27,277 -584	-2%	-$25.1K	﹤0.01%	879
2018 Q3	$1.37M	Buy	+27,861	New	+$1.38M	﹤0.01%	834
2018 Q2	–	Sell	-14,800	Closed	-$676K	–	1555
2018 Q1	$676K	Buy	+14,800	New	+$618K	﹤0.01%	1147
2013 Q3	–	Sell	-35,387	Closed	-$228K	–	2596
2013 Q2	$228K	Buy	+35,387	New	+$208K	﹤0.01%	1768

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Holdings's SUPN Position: Q4 2025 in Review

Nomura Holdings sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 24,869 shares — an estimated $1.19M sold.

Nomura Holdings first reported a position in SUPN in Q2 2013 and held it in 9 quarters. The position peaked at $1.58M in Q1 2019. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

Nomura Holdings reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Nomura Holdings sold 24,869 Supernus Pharmaceuticals shares in Q4 2025, an estimated $1.19M.
Nomura Holdings first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Nomura Holdings's Supernus Pharmaceuticals position peaked at $1.58M in Q1 2019.
333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Nomura Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.